|Budget Amount *help
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2021: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2020: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|Outline of Final Research Achievements
Drug-induced pulmonary fibrosis is caused by various drugs such as anticancer drugs, but the elucidation of its mechanism is currently delayed. The purpose of this study was to clarify the relationship between drug-induced pulmonary fibrosis and microRNA (miRNA). The effects of drugs (bleomycin, methotrexate, etc.) were analyzed using A549/ABCA3 cells having the characteristics of alveolar type II epithelial cells and pulmonary fibrosis model animals of mice and rats. As a result, it was found that miR-34a and miR-222 may be a cause of fibrosis and useful as a biomarker or therapeutic target of drug-induced pulmonary fibrosis, while miR-484 may be useful as a biomarker.